Expect near-term selling pressure as registered shareholders and White Lion can immediately distribute ADSs into the market. Monitor for any new draw requests under the White Lion purchase agreement and for any reverse-split or capital restructuring announcements that could alter the ADS-to-ordinary ratio.
Price Chart
Executive Summary
Akari Therapeutics' S-3 registration statement (file 333-297257) became effective on July 13, 2026, allowing selling shareholders to resell up to 5,999,999 ADSs tied to the May 2026 private placement. The company receives no proceeds from these resales, and the active shelf, combined with the separate White Lion Capital facility (also effective), creates a multi-source dilution overhang for the $23M market cap biotech.
Key Facts
- S-3 registration (333-297257) effective July 13, 2026 — up to 5,999,999 ADSs registered for resale by selling shareholders
- Company receives no proceeds from the resale of these shares
- Prior S-3 analysis (July 2) noted only ~$0.5M cash on hand, making warrant exercise proceeds critical for funding
- Separate White Lion facility (S-1/A effective) allows up to $25M in additional share sales at company's discretion
- Market cap is ~$23M; two concurrent effective resale registrations imply substantial near-term selling pressure
Financial Impact
Up to 5,999,999 ADSs (plus potential White Lion draws) eligible for immediate resale, representing significant dilution against a ~$23M market cap; no new cash to the company from these sales
Risk Factors
- Sustained dilution from multiple effective resale registrations without corresponding capital infusion
- Cash runway concerns — only $0.5M cash per prior analysis, with no new primary offering proceeds
- Potential for accelerated selling if ADS price declines trigger forced liquidations by selling shareholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002279 |
| Document: 9999999995-26-002279-index.html | 9999999995-26-002279 |
| Document: 9999999995-26-002279.txt | 9999999995-26-002279 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | DEF 14A | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $7.63 (+1.19%) |
Jul 14, 2026 14w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $7.63 (+43.14%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $7.63 (−46.31%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $7.63 (+26.71%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $7.63 (−65.40%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $7.63 (+57.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers